Osteosarcoma is the most common primary malignant tumour of the bone. Osteosarcoma
incidence is bimodal, peaking at 18 and 60 years of age, and is slightly more common in …

Osteosarcoma Osteosarcoma, which is most common in people 10 to 30 years of age, is
generally treated with resection and adjuvant chemotherapy. Detection of gene …

Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy.
Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T …

Improving the survival of patients with osteosarcoma has long proved challenging, although
the treatment of this disease is on the precipice of advancement. The increasing feasibility of …

Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced
soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary …

Osteosarcoma is the most common primary bone cancer in children and young adults.
Limited progress has been made in improving the survival outcomes in patients with …

Background Afamitresgene autoleucel (afami-cel) showed acceptable safety and promising
efficacy in a phase 1 trial (NCT03132922). The aim of this study was to further evaluate the …

Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes,. The clinical presentation of patients with different subtypes is often …

Osteosarcoma is the most frequent primary bone tumor with poor prognosis. Through RNA-
sequencing of 100,987 individual cells from 7 primary, 2 recurrent, and 2 lung metastatic …

Soft‐tissue sarcomas (STS) are rare tumors that account for 1% of all adult malignancies,
with over 100 different histologic subtypes occurring predominately in the trunk, extremity …